佐力藥業(300181.SZ):科濟藥業於6月7日開始公開發售
格隆匯6月8日丨佐力藥業(300181.SZ)公佈,近日,公司根據孫公司浙江佐力創新醫療投資管理有限公司參股公司CARsgen Therapeutics Holdings Limited (科濟藥業控股有限公司,“科濟藥業”)的通知,從香港聯交所網站查詢獲悉,科濟藥業於2021年6月7日開始公開發售,具體信息如下:
全球發售的發售股份數目:9474.7萬股股份(視乎超額配股權行使與否而定);
香港發售股份數目:947.5萬股股份(可予重新分配);
國際發售股份數目:8527.2萬股股份(可予重新分配及視乎超額配股權行使與否而定);
最高發售價:每股發售股份32.80港元,另加1.0%經紀佣金、0.0027%證監會交易會費及0.005%聯交所交易費;
面值:每股股份0.00000025美元;股份代號:02171;
預期股份開始在聯交所買賣:2021年6月18日(星期五)上午九時正。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.